Pittman Scott M. - 29 Jun 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: AURX
Reported as of: 29 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 21:00:41 UTC
Prior SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Jorden, attorney-in-fact

Key filing fact

Pittman Scott M. filed Form 4 for Nuo Therapeutics, Inc. (AURX) on 02 Jul 2026.

Key facts

This page summarizes Pittman Scott M.'s Form 4 filing for Nuo Therapeutics, Inc. (AURX).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 21:00.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674752 Primary reporting owner

Pittman Scott M.

Relationship: Director, 10%+ Owner
Address: C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON
Signature: /s/ David Jorden, attorney-in-fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AURX transaction

Common Stock

Options Exercise

Transaction value
Shares: +40,000
Change %: +0.74%
Price: $1.00^*
Shares after: 5,440,000
Date: 30 Jun 2026
Ownership: Direct

AURX transaction

Common Stock

Tax liability

Transaction value
Shares: -39,604
Change %: -0.73%
Price: $1.01^*
Shares after: 5,400,396
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURX transaction Derivative

Option to purchase common stock

Options Exercise

Transaction value
Shares: -40,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $1.00
Footnotes: F2

AURX transaction Derivative

Option to purchase common stock

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 29 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.01
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

Footnote F2

15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.

Footnote F3

The options fully vest as of June 30, 2027.